StreetInsider.com News Articles

Cingulate closes $12 million private placement at market price

Tue, 17 Feb 2026 08:02:38 +0000

Cingulate Inc. (NASDAQ: CING) completed a $12 million private investment in public equity financing led by affiliates of Falcon Creek Capital Advisor LLC, the biopharmaceutical company announced.

The private placement was priced at $5.04 per share, matching the Nasdaq closing price on January 26, 2026. The transaction includes 80% warrant coverage and requires all participating investors to observe a 180-day lock-up period.

The financing structure includes convertible preferred stock that accrues 12% annualized interest until conversion, subject to stockholder approval. Warrants carry a three-year term and are exercisable upon stockholder approval. Total potential proceeds could reach $21.4 million if warrants are exercised.

"This

Cingulate closes $12 million private placement at market price

Tue, 17 Feb 2026 08:02:38 +0000

Cingulate Inc. (NASDAQ: CING) completed a $12 million private investment in public equity financing led by affiliates of Falcon Creek Capital Advisor LLC, the biopharmaceutical company announced.

"This

Cingulate closes $12 million private placement at market price

Tue, 17 Feb 2026 08:02:38 +0000

Cingulate Inc. (NASDAQ: CING) completed a $12 million private investment in public equity financing led by affiliates of Falcon Creek Capital Advisor LLC, the biopharmaceutical company announced.

"This

Cingulate closes $12 million private placement at market price

Tue, 17 Feb 2026 08:02:38 +0000

Cingulate Inc. (NASDAQ: CING) completed a $12 million private investment in public equity financing led by affiliates of Falcon Creek Capital Advisor LLC, the biopharmaceutical company announced.

"This

Cingulate closes $12 million private placement at market price

Tue, 17 Feb 2026 08:02:38 +0000

Cingulate Inc. (NASDAQ: CING) completed a $12 million private investment in public equity financing led by affiliates of Falcon Creek Capital Advisor LLC, the biopharmaceutical company announced.

"This

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC (“Falcon Creek Capital”).

“This long-term financing from life science–focused institutional investors represents strong validation of our strategy, our technology, and the significant commercial opportunity ahead. The transaction included insider participation underscoring our confidence in the value we are building and our commitment to standing shoulder-to-shoulder

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 17 Feb 2026 08:00:00 +0000

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Thu, 13 Nov 2025 08:00:00 +0000

Industry Veteran Bryan Downey Named Chief Commercial Officer
NDA Accepted with May 2026 PDUFA Date
Commercial Supply Agreement Executed

KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights.

Recent Highlights (Post-Q3)